NACLC 2022

Confirmed Exhibitors

The IASLC 2022 North America Conference on Lung Cancer (NACLC 2022) offers a tremendous opportunity to market to one of the leading gatherings of researchers, clinicians, and professionals in the field of lung cancer and thoracic oncology.

Exhibition Hall Hours

Saturday, September 249:30 - 18:00
Sunday, September 259:15 - 12:30

Exhibit Floor Plan

The IASLC 2022 North America Conference on Lung Cancer would like to thank the following exhibitors (listed in alphabetical order) for their support:


AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at


Amgen is a worldwide leader in biotechnology. For more than forty years, we’ve pursued some of the greatest challenges facing human health, marrying science and technological innovation with the passion of our staff, to serve patients and find new solutions that meet the growing demand for better quality healthcare for more people worldwide. (

Blueprint Medicines

Blueprint Medicines is a global precision therapy company that aims to invent medicines for people with cancer and blood disorders. (

Eli Lilly & Company

Lilly unites caring with discovery to create medicines that make life better for people around the world. (

EMD Serono

At EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany, in the US and Canada, our scientific approach in oncology focuses on oncogenic pathways, immuno-oncology, and DNA damage response. To deliver breakthrough cancer therapies, we complement our internal expertise and development programs with scientific collaborations to improve trial designs, accelerate treatment development, and partner on exciting asset programs and integrated innovations. We aim to deliver personalized treatment options that may potentially transform cancer care. (


For more than 40 years, we’ve been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions. We are headquartered in South San Francisco, California. (

Genomic Testing Cooperative

Genomic Testing Cooperative (GTC) is a different kind of cancer diagnostic laboratory. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices, and medical professionals to share resources which create efficiencies in cost, turnaround time, and quality. Customers can benefit from either of our two business models which best suits their needs. The first is a traditional reference lab model in which GTC can white label our report and allow the co-op member to build their NGS business with their own branding. The second model helps labs internalize and turn their NGS oncology send-out volume into a revenue-generating opportunity with GTC’s technology. In creating a network of co-op partners, we help results get to physicians faster, share knowledge more easily, and generate better outcomes for patients. (

Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening. (


At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at Follow us at


Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing medicines for people with serious diseases — often with limited or no options. (


At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types. (


Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit and follow @Novocure on LinkedIn and Twitter. (


Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions. (


At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We ensure a tight connection from research to development to commercialization and rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to patients. Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide. For more information, visit


Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. (

Contact Us

For information regarding promotion & advertising, symposia and exhibit opportunities, please contact:

International Association for the Study of Lung Cancer (IASLC) 
[email protected] 
Phone: +1 720 598 1951 
Fax: +1 720 325 2848